The GCP Center of The Oncology Hospital of the Medical College was awarded the best clinical research institution in China in 2019.

September 21-23, hosted by the Nanjing Municipal People's Government, "2020 Nanjing International New Medicine and Life And Health Industry Innovation Investment Summit" was held. The leaders of state ministries, representatives of national academic associations, more than 10 Chinese and foreign academicians, more than 40 experts from university research institutes and clinical trial institutions, more than 50 fund management partners and more than 100 heads of listed and proposed listed enterprises discussed the current situation and development direction of China's innovative biopharmaceutical industry.
Summit has released the first annual "China Biopharmaceutical Industry Chain Innovation List". The GCP Center of the Oncology Hospital of the Chinese Academy of Medical Sciences was awarded the best award in this year's list, the Benchmark Award (the only experimental institution that has won the award), and was named the best clinical trial research institution in 2019.
the list was organized by the editorial board of pharmaceutical journal Pharmaceutical Progress, co-sponsored by the Chinese Pharmaceutical Society and the Chinese Pharmaceutical University, and the data were derived from the new drug research and development monitoring database, the comprehensive drug database and the drug database. "China Biopharmaceutical Industry Chain Innovation List" is the first domestic covering the entire biopharmaceutical industry chain awards, selected "production, research and development of medical" new drug research and development participants outstanding representatives. Under the guidance of the national "major new drug creation" major special project, from the target novelty, technological advancedness, clinical needs and research and development investment and other 12 dimensions, set the score standard, by the academician expert group video link, online voting and weighted comprehensive assessment.
As the leading unit of anti-tumor clinical research in China, the Oncology Hospital of the Chinese Academy of Medical Sciences has been under the leadership of experts such as Hejie, Sun Yan and Professor Xu Binghe since the launch of the first clinical trial of anti-tumor drugs in New China in 1960. CP Center aims to continue to lead the development of China's clinical research industry, to achieve the international influence and international leadership of China's anti-tumor clinical research as the goal, to build the world's leading anti-tumor clinical research, all-round, solid and benign operation of the non-profit medical center as a committed development goal.
2017, the GCP Center of the Oncology Hospital of the Chinese Academy of Medical Sciences took the lead in realizing the centralization system in China, establishing an integrated standardized management and one-stop operation model, and improving the efficiency and quality of clinical research. In 2018, the hospital took the lead in the domestic release of the "Center Work Manual", fully open GCP center workflow, to facilitate the communication between the bid parties. In 2019, GCP Center clinical trial integrated management platform online operation, the realization of more than a thousand clinical trial projects in hospitals in real-time dynamic supervision, the use of advanced technology to help clinical trial management. This year, our hospital was approved the first batch of Beijing research ward demonstration construction units, a total area of 1400 square meters of GCP center ward officially opened, clinical trial operating environment has been further improved.
.